In conclusion, our findings provide additional support for the pathological role of CXCL12–CXCR4 signalling in pancreatic cancer, and demonstrate, for the first time, a role for this axis in drug resistance. This evidence concerns the gene CXCL12 and pancreatic neoplasm.